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pleted every 6 months, as well as the Subjective Side Effect Rating Scale, assessing 
patient distress over extrapyramidal symptoms, weight gain, sedation and sexual 
dysfunction over the past seven days. A random-effects regression analysis was 
used to estimate the impact of these adverse events on utilities with adjustment 
on disease severity and other potential confounding factors. Results: Our sample 
consisted in 1208 patients with schizophrenia. At baseline, the mean EQ-5D utility 
was 0.73 (0.28), 57.7% of patients reported extrapyramidal symptoms, 46.2% weight 
gain, 46.5% sedation and 27.8% sexual dysfunction. The regression model showed 
that extrapyramidal symptoms, weight gain, sedation and sexual dysfunction were 
associated with reductions in utility of 0.054 (0.008), 0.018 (0.008), 0.021 (0.008) and 
0.032 (0.011) points, respectively. ConClusions: This study shows that side effects 
are associated with significant decrements in EQ-5D utility, especially extrapyrami-
dal symptoms. Additionally, adverse events may have an indirect negative impact 
on quality of life, since they may be associated with reduced treatment adherence, 
and therefore reduced treatment effectiveness.
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objeCtives: Examine the association between residual symptoms of depression 
(depressive symptoms still present after 3 months of antidepressant treatment) 
and patient reported mental and physical quality of life. Methods: A subset of 
patients from the 2012 National Health and Wellness survey (n = 71,157), an annual 
general health survey of US adults, was used in this analysis. Inclusion criteria 
were a diagnosis of depression and treatment with an antidepressant medication 
for at least 3 months (n = 5,354). Residual symptoms were measured via the 9-item 
Personal Health Questionnaire (PHQ-9) depression scale and quality of life was 
measured via the SF-36v2 mental and physical component summary scores (MCS 
and PCS). Inter-relationships among symptoms were assessed using Pearson cor-
relations, and Ordinary Least Squares (OLS) regression was used for MCS and PCS 
analyses. Results: The most common residual symptoms were fatigue (49.6%; 
“Feeling tired or having little energy”) and sleep problems (42.8%; “Trouble falling 
or staying asleep, or sleeping too much”). All residual symptoms were more strongly 
correlated with MCS scores (r = -.37 to -.60) compared with PCS scores (r = -.06 to 
-.26) (p< .01). In the OLS regression models, anhedonia (“Little interest or pleasure in 
doing things”) and sadness (“Feeling down, depressed, or hopeless”) held the strong-
est associations with lower MCS scores (p< .001), whereas fatigue held the strongest 
association with lower PCS scores (p< .001) after controlling for other residual symp-
toms. ConClusions: Residual symptoms of depression persist despite adequate 
duration of antidepressant treatment and are associated with poorer quality of life. 
Anhedonia and sadness were most strongly associated with lower mental quality 
of life while fatigue was most strongly associated with lower physical quality of life.
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objeCtives: The efficacy of lurasidone in reducing depression symptoms and 
improving functioning among patients with bipolar depression has been previ-
ously demonstrated. This analysis examines the direct and indirect effect (mediated 
through improvement in depression symptoms) of lurasidone in improving patient 
functioning. Methods: Data from a 6-week, double-blind, placebo-controlled trial 
assessing the effect of treatment [lurasidone (20–60 mg or 80-120 mg) versus pla-
cebo] in bipolar depression was used. Patient functioning was measured using a vali-
dated patient reported outcomes scale, Sheehan Disability Scale (SDS), that assessed 
functioning in work/school, family, and social life (higher scores indicate greater 
disability). Depression symptoms were measured using the 10-item Montgomery-
Asberg Depression Rating Scale (MADRS; higher scores indicate greater severity). 
Path analyses evaluated total effect (β 1), as well as the indirect effect (β 2*β 3) and 
direct effect (β 4) of treatment on SDS change, using standardized beta path coef-
ficients and baseline scores as covariates. The direct effect of treatment on SDS 
change and indirect effects accounting for mediation through MADRS change was 
examined for statistical significance and magnitude. Results: Path analyses (n 
= 258) revealed a moderate total effect for treatment predicting improvement in SDS 
score (β 1= -0.40, p= 0.001). Treatment predicted improvement in MADRS (β 2= -0.33, 
p= 0.009), which subsequently predicted improvement in SDS (β 3= 0.70, p< 0.001; 
indirect effect = -0.23). The direct effect was small yet significant (β 4= -0.17, p= 0.04), 
indicating partial mediation. Indirect and direct effects accounted for 57% and 43% 
of the total effect, respectively. The full mediation model with indirect and direct 
effects explained 61.7% of the variation in the change in SDS scores. ConClusions: 
These analyses show that improvement in patient functioning among patients 
on lurasidone was largely mediated through reduction in depression symptoms. 
Lurasidone also had a small but statistically significant direct effect in improving 
patient functioning that was independent of improvements in depression within 
a 6-week study duration.
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objeCtives: This study aimed to determine the validity (construct, known-
groups), reliability (internal consistency), and floor and ceiling effects of the 12 
ratio (OR): 9.42; 95% confidence interval (CI): 8.55-10.39), female sex (OR: 1.11; 95%CI: 
1.01-1.22), age 55-64 (OR: 1.26; 95%CI: 1.09-1.46) relative to age 25-34, and Hispanic 
(OR: 1.37; 95%CI: 1.05-1.81) relative to white. An incremental $10K in BY inpatient 
admission cost was also associated with greater likelihood of success (OR: 1.11; 
95%CI: 1.08-1.15). Accounting for baseline differences between treatment cohorts 
using IPW, PP use was associated with a 26% increase in the likelihood of continuity 
achievement compared to other AP use (OR: 1.26; 95%CI: 1.14-1.39). ConClusions: 
Baseline factors associated with better performance on the HEDIS Continuity of AP 
Medications measure were prior year adherence, use of PP therapy, higher inpatient 
costs, older age, female gender, and Hispanic ethnicity.
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objeCtives: Pediatric Attention Deficit/Hyperactivity Disorder (ADHD) patients are 
usually prescribed combination of psychotropic agents. This study looked at the 
impact of atypical antipsychotic (AAP) use on long acting stimulant (LAS) persis-
tence in children and adolescents with ADHD. Methods: This study used 4 years 
(January 2004 to December 2007) of IMS LifeLink™ claims data involving 6-16 years 
old youths with ADHD and at least 1 LAS prescription between July 2004 to December 
2006 and continuous eligibility 6 months before and 1 years after the index LAS pre-
scription. Persistence was measured by summing the total number of days a patient 
remained on the index LAS from the index prescription date with allowable gap of 
no more than 30 days. Multivariate Cox proportional hazards regression was used 
to examine the impact of concomitant atypical antipsychotic use on persistence of 
stimulants. Results: The study cohort consisted of 39,981 subjects. Of these, 1,560 
(3.90%) received LAS and AAP polypharmacy and the rest 38,421 (96.10%) received 
LAS monotherapy. Bivariate analyses revealed that concomitant users had longer 
persistence (by 71 days) than the stimulant alone users. Cox proportional hazards 
regression revealed that concomitant atypical antipsychotic use improved LAS per-
sistence by 15% (HR= 0.85, CI= 0.76-0.94) in comparison to the non-users among LAS 
recipients. Other factors such as age, region, season, coexisting mental health condi-
tions, use of co-medications, and general mental health status influenced the LAS 
treatment persistence among children and adolescents with ADHD. ConClusions: 
Use of atypical antipsychotics improved LAS treatment persistence in children and 
adolescents with ADHD. Various patient, clinical and treatment factors were associ-
ated with the LAS treatment persistence in ADHD youths. Understanding of these 
factors can help to improve persistence to LAS treatment.
PMH60
anTidePressanT adHerence in older adulTs and differenT qualiTy 
of life ouTcoMe Measures
Lamoureux-Lamarche C.1, Vasiliadis H.M.1, Gontijo-Guerra S.1, Preville M.2
1Université de Sherbrooke, Longueuil, QC, Canada, 2Unviersité de Sherbrooke, Longueuil, QC, 
Canada
objeCtives: The aim of this study was to determine the impact of antidepressant 
adherence on health-related quality of life and life satisfaction in a representative 
community sample of older adults. Methods: The data were obtained from the 
ESA (Étude sur la Santé mentale des Aînés) Services study that included a large 
sample of older adults (n= 1809) aged 65 years and over who consulted and were 
recruited in a primary care practices. HRQOL was measured using the EuroQOL-5D 
which assessed utility values, from the general population perspective and the 
EQ-Visual Analog Scale (EQ-VAS) was used to measure self-reported health sta-
tus from the patient perspective. The CASP was used to measure life satisfaction. 
Common mental disorders were based on DSM-IV (Diagnostic and Statistical Manual 
of Mental Disorders, Fourth Edition) criteria. Antidepressant use was obtained from 
administrative databases. A 4 level dummy variable was constructed to consider the 
presence of depression/anxiety (MD) and antidepressant use (MD X AD). Adherence 
to antidepressant was measured using the medication possession ratio (MPR ≥ 
80%). Multivariate linear regression models were used to study HRQOL and life 
satisfaction as a function of depression/anxiety X antidepressant use (MD X AD) 
controlling for antidepressant use, the presence of chronic and physical disorders 
and other socio-demographic factors. Results: HRQOL measured by the EuroQOL 
was significantly associated with age, cognitive impairment and the presence of 
depression. Self-reported health status measured by the EQ-VAS was associated 
with age, number of chronic illnesses, cognitive impairment. The CASP was associ-
ated with age, and PTSD. Antidepressant use was associated with a lower HRQOL 
and a lower life satisfaction. ConClusions: The study showed that the determi-
nants associated with HRQOL and life satisfaction from the patient and general 
population perspective differs. Future studies should focus on determining other 
factors that influence HRQOL and life satisfaction in older adults.
PMH61
uTiliTy decreMenTs associaTed wiTH TreaTMenT-relaTed adverse 
evenTs in scHizoPHrenia
Millier A.1, Amri I.2, Toumi M.3
1Creativ-Ceutical, Paris, France, 2Creativ-Ceutical, Tunis, Tunisia, 3University Claude Bernard Lyon 
1, Lyon, France
objeCtives: Several studies have estimated health state utilities for patients 
with schizophrenia according to disease stage. However, the quality of life of these 
patients is also largely dependent on treatment-related adverse events, and there 
is paucity of data on utilities associated with those adverse events. The objective 
of this study was to estimate utility decrements associated with treatment-related 
adverse events in patients with schizophrenia, using data from an observational 
study. Methods: We used data from EuroSC, a multicenter 2-year cohort study 
conducted in France, England and Germany. The EQ-5D questionnaire was com-
